Two-stage matching-adjusted indirect comparison

被引:3
|
作者
Remiro-Azocar, Antonio [1 ,2 ]
机构
[1] Bayer PLC, Med Affairs Stat, 400 South Oak Way, Reading, Berks, England
[2] UCL, Dept Stat Sci, 1-19 Torrington Pl, London, England
关键词
Health technology assessment; Indirect treatment comparison; Matching-adjusted indirect comparison; Covariate adjustment; Covariate balance; Inverse probability of treatment weighting; Evidence synthesis; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; ANCHORED INDIRECT COMPARISONS; GUANFACINE EXTENDED-RELEASE; PROPENSITY SCORE; INVERSE PROBABILITY; CAUSAL INFERENCE; VARIABLE SELECTION; PRACTICAL GUIDE; PERFORMANCE; TRIAL;
D O I
10.1186/s12874-022-01692-9
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Anchored covariate-adjusted indirect comparisons inform reimbursement decisions where there are no head-to-head trials between the treatments of interest, there is a common comparator arm shared by the studies, and there are patient-level data limitations. Matching-adjusted indirect comparison (MAIC), based on propensity score weighting, is the most widely used covariate-adjusted indirect comparison method in health technology assessment. MAIC has poor precision and is inefficient when the effective sample size after weighting is small. Methods A modular extension to MAIC, termed two-stage matching-adjusted indirect comparison (2SMAIC), is proposed. This uses two parametric models. One estimates the treatment assignment mechanism in the study with individual patient data (IPD), the other estimates the trial assignment mechanism. The first model produces inverse probability weights that are combined with the odds weights produced by the second model. The resulting weights seek to balance covariates between treatment arms and across studies. A simulation study provides proof-of-principle in an indirect comparison performed across two randomized trials. Nevertheless, 2SMAIC can be applied in situations where the IPD trial is observational, by including potential confounders in the treatment assignment model. The simulation study also explores the use of weight truncation in combination with MAIC for the first time. Results Despite enforcing randomization and knowing the true treatment assignment mechanism in the IPD trial, 2SMAIC yields improved precision and efficiency with respect to MAIC in all scenarios, while maintaining similarly low levels of bias. The two-stage approach is effective when sample sizes in the IPD trial are low, as it controls for chance imbalances in prognostic baseline covariates between study arms. It is not as effective when overlap between the trials' target populations is poor and the extremity of the weights is high. In these scenarios, truncation leads to substantial precision and efficiency gains but induces considerable bias. The combination of a two-stage approach with truncation produces the highest precision and efficiency improvements. Conclusions Two-stage approaches to MAIC can increase precision and efficiency with respect to the standard approach by adjusting for empirical imbalances in prognostic covariates in the IPD trial. Further modules could be incorporated for additional variance reduction or to account for missingness and non-compliance in the IPD trial.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Matching-adjusted indirect comparison for treatment of NTRK fusion cancer with larotrectinib versus entrectinib
    Garcia-Foncillas, J.
    Bokemeyer, C.
    Italiano, A.
    Keating, K.
    Paracha, N.
    Fellous, M.
    Marian, M.
    Fillbrunn, M.
    Gao, W.
    Ayyagari, R.
    Lassen, U. N.
    ANNALS OF ONCOLOGY, 2021, 32 : S401 - S401
  • [22] Comparative effectiveness of ozanimod versus dimethyl fumarate: results of a matching-adjusted indirect comparison
    Cohan, S.
    Kumar, J.
    Arndorfer, S.
    Zhu, X.
    Zivkovic, M.
    Tencer, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 140 - 140
  • [23] MATCHING-ADJUSTED INDIRECT COMPARISONS: A SIMULATION STUDY OF STATISTICAL PERFORMANCE
    Signorovitch, J.
    Ayyagari, R.
    Cheng, D.
    Wu, E. Q.
    VALUE IN HEALTH, 2013, 16 (03) : A48 - A48
  • [24] PROTECT and NefIgArd two-year proteinuria and eGFR outcomes in adults with IgA nephropathy: matching-adjusted indirect comparison
    Gong, Wu
    Diva, Ulysses
    Bensink, Mark
    Chai, Xinglei
    Gao, Sophie
    Hendry, Bruce
    Mercer, Alex
    Zhou, Zheng-Yi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [25] PROTECT and NefIgArd two-year proteinuria and eGFR outcomes in adults with IgA nephropathy: matching-adjusted indirect comparison
    Gong, Wu
    Diva, Ulysses
    Bensink, Mark
    Chai, Xinglei
    Gao, Sophie
    Hendry, Bruce
    Mercer, Alex
    Zhou, Zheng-Yi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I744 - I745
  • [26] Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison
    Mahon, Ronan
    Tiwari, Santosh
    Koch, Mirja
    Ferraris, Matias
    Betts, Keith A.
    Wang, Yan
    Gao, Sophie
    Proot, Pascal
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2024, 13 (03)
  • [27] Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
    Strand, Vibeke
    Betts, Keith A.
    Mittal, Manish
    Song, Jinlin
    Skup, Martha
    Joshi, Avani
    RHEUMATOLOGY AND THERAPY, 2017, 4 (02) : 349 - 362
  • [28] Matching-adjusted indirect treatment comparison of guselkumab and ixekizumab in patients with moderate-to-severe psoriasis
    Varu, Abhishek
    Cameron, Chris
    Diels, Joris
    Hutton, Brian
    McElligott, Sean
    Schubert, Agata
    van Sanden, Suzy
    Villacorta, Reggie
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB187 - AB187
  • [29] A MATCHING-ADJUSTED INDIRECT COMPARISON OF FILGOTINIB VERSUS TOFACITINIB FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Lu, X.
    Gray, E.
    Xin, Y.
    Zhou, J.
    Jairath, V
    Lindsay, J. O.
    VALUE IN HEALTH, 2022, 25 (07) : S321 - S321
  • [30] COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND PONESIMOD FOR RELAPSING MULTIPLE SCLEROSIS: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Swallow, E.
    Pham, T.
    Patterson-Lomba, O.
    Yin, L.
    Gomez-Lievano, A.
    Liu, J.
    Tencer, T.
    Gupte-Singh, K.
    VALUE IN HEALTH, 2022, 25 (07) : S300 - S300